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Aortic valve disease, in particular stenosis (AS), is the most common valvular abnormality 
detected in the aging population whit an AS prevalence of 3 to 5% in the population over 75 
years of age (1, 2). Valvular aortic stenosis without accompanying mitral valve disease is 
more common in men than in women. A clear increase in prevalence of aortic sclerosis has 
been seen with age: 20% in patients aged 65–75 years, 35% in those aged 75–85 years, and 
48% in patients older than 85 years. For the same age-groups, 1.3%, 2.4%, and 4% have frank 
aortic stenosis (3).  
1.2 Etiology 
AS is the obstruction of blood flow across the aortic valve. AS has several etiologies 
including rheumatic fever, congenital unicuspid or bicuspid valve, and degenerative calcific 
changes of the valve.  Rheumatic heart disease is the main cause of valvular heart disease 
worldwide, but fewer than 10% of AS cases in the United States and Western Europe are 
rheumatic. In contrast, senile, calcific disease of the aortic valve and bicuspid valve disease 
are responsible for the vast majority of AS cases in those countries. Since the incidence of AS 
increases with age and the Western population as a whole is aging, increased numbers of 
patients presenting with AS are expected in the near future. Currently, the incidence of AS is 
estimated to be 1−2% among those over 65 years of age and 4% among octagenarians. 
Rheumatic AS is rarely an isolated disease and usually occurs in conjunction with mitral 
valve stenosis. Rheumatic AS is characterized by diffuse fibrous leaflet thickening of the 
tricuspid valve with fusion of the commissures with scarring and eventual calcification of 
the cusps. A congenital malformation of the valve may also result in stenosis and is the most 
common cause in young adults. Bicuspid aortic valve is the most common cause of aortic 
stenosis in patients under age 65. About 2% of people are born with aortic valves that have 
only two cusps (bicuspid valves). Although bicuspid valves usually do not impede blood 
flow when the patients are young, they do not open as widely as normal valves with three 
cusps. Therefore, blood flow across the bicuspid valves is more turbulent, causing increased 
wear and tear on the valve leaflets. Over time, excessive wear and tear leads to calcification, 
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scarring, and reduced mobility of the valve leaflets. About 10% of bicuspid valves become 
significantly narrowed, resulting in the symptoms and heart problems of aortic stenosis. 
The most common cause for AS in adults is senile degenerative AS, with the calcification 
of a normal trileaflet or a congenital bicuspid valve (4). Even if it was considered to be the 
result of years of mechanical stress on an otherwise normal valve, the evolving concept is 
that the degenerative process leads to proliferative and inflammatory changes.  Calcific 
aortic-valve disease refers to progressive aortic leaflet thickening and calcification, 
beginning with the early lesion of aortic-valve sclerosis leading to advanced leaflet 
disease of aortic-valve stenosis, characterized by restricted leaflet motion and outflow 
obstruction. The pathobiology of the aortic-valve lesion involves an atheromatous, 
osteogenic, inflammatory process sharing some histologic similarities with coronary 
atherosclerosis (5)  
1.3 Pathophysiology 
Valvular aortic stenosis results in chronic left ventricular pressure overloading. At any stage 
of life, however, the natural history of aortic stenosis largely reflects the functional integrity 
of the mitral valve. As long as adequate mitral valve function is maintained, the pulmonary 
bed is protected from the systolic pressure overloading imposed by aortic stenosis. 
Compensatory concentric left ventricular hypertrophy allows the pressure-overloaded 
ventricle to maintain stroke volume with modest increases in diastolic pressure, and 
patients remain asymptomatic for many years. In early stages the development of concentric 
hypertrophy appears to be an appropriate and beneficial adaptation to compensate for high 
intracavitary pressures. Unfortunately, this adaptation often carries adverse consequences. 
The hypertrophied heart may have reduced coronary blood flow and also exhibit a limited 
coronary vasodilator reserve, even in the absence of epicardial coronary artery disease, 
that`s why one of the symptoms is angina. In later stages of severe AS, cardiac output 
declines, and the pulmonary artery pressure rises, leading to pulmonary hypertension. The 
first symptom of this condition is increasing shortness of breath and the last consequence is 
heart failure. The onset of any of the classic symptoms of left ventricular outflow 
obstruction—angina, syncope, or heart failure—in a patient with valvular aortic stenosis 
indicates advanced valve disease and should be carefully and promptly evaluated. Syncope 
most commonly is due to the reduced cerebral perfusion that occurs during exertion 
secondary to the decrease in arterial pressure consequent to peripheral vasodilation in the 
presence of a fixed cardiac output. For years the cause of the calcification of the aortic valve 
was thought to be the passive accumulation of calcium in the valve leaflets, causing nodular 
deposits and an eventual stenosis. Clinical studies have demonstrated that the risk factors 
for this process include hypercholesterolemia, diabetes, smoking, hypertension, male sex, 
and elevated high sensitivity C-reactive protein (6), suggesting that calcification of the aortic 
valve results from an inflammatory process triggered by these factors of atherosclerotic risk 
and that drug therapies to retard this process may be a useful strategy in the future. 
Hyperuricemia has been identified as another risk factor for development of aortic valvular 
disease. Calcific AS is also observed in a number of other conditions, including Paget disease 
of bone and end-stage renal disease. Ochronosis with alkaptonuria is another rare cause of 
AS, which also can cause a rare greenish discoloration of the aortic valve. Recent 
experimental models have shown that there is a relationship between hypercholesterolemia 
and the development of aortic valvular disease (7).  Studies of human tissue also suggest 
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that the development of aortic valvular calcification represents an active cellular biology. 
O’Brien et al. have described the early valvular lesion (aortic sclerosis) as an entity very 
similar to the early lesion of the atherosclerotic plaque (8). These lesions show similarities to 
the atherosclerotic process, with a predominance of ‘atherogenic’ lipoproteins, especially 
LDL and lipoprotein(a), evidence of LDL oxidation, inflammatory cellular infiltrates and the 
development of calcification. The presence of lipids stimulates the production of many 
factors such as modified TGF-b1, tumor necrosis factor and cytokines in the aortic valve 
leaflets (9). In particular early valvular sclerotic lesions demonstrate a chronic inflammatory 
cell infiltrate (macrophages and T lymphocytes), lipid accumulation (apolipoprotein [apo] B, 
apo(A) and apo(E) and α-actin–expressing cells in the lesion and adjacent fibrosa; end-stage 
calcified valves contain mature lamellar bone with expression of specific bon markers 
important in the development of osteoblast bone formation (10). In addition, angiotensin-
converting enzyme (ACE) and angiotensin II type 1 (AT1) and type 2 (AT2) receptors are 
present in stenotic aortic valves, implicating this signaling pathway in the disease process 
(11). These observations are analogous to the cellular findings in vascular atherosclerosis 
and corroborate epidemiological studies that showed similar associations of clinical risk 
factors with both atherosclerosis and aortic valve disease (12). The mechanism for valvular 
calcification is similar to skeletal bone formation and that calcification occurs in areas of 
neoangiogenesis, which is stimulated by an active inflammatory process and the release of 
vascular endothelial growth factor (VEGF). VEGF is well known to play a key role in 
angiogenesis in pathological inflammatory diseases.(13) Deckers et al (14) have suggested 
that VEGF regulates bone remodeling by attracting endothelial cells and by stimulating 
osteoblast differentiation. Our findings indicate that VEGF is localized to cells in 
inflammatory regions of the valve fibrosa, specifically the macrophages and myofibroblasts. 
Rajamannan recently demonstrated that an osteoblast phenotype is associated with 
nonrheumatic, degenerative calcific aortic stenosis. The current data, including the 
production of osteopontin and osteocalcin proteins (both osteoblast cell products) and 
proliferating myofibroblast cells synthesizing bone matrix proteins, indicate that a similar 
osteoblast-like process that occurs in degenerative calcific aortic stenosis develops in the 
calcification process in rheumatic valves (10). Although calcification in rheumatic valves has 
been described in the literature for years, the cellular mechanisms responsible for the 
calcification have not been previously described. These new observations support the 
hypothesis that mineralization of rheumatic cardiac valve tissue is similar to skeletal bone 
formation that is associated with neoangiogenesis and show that studying this disease 
process will provide important information on the treatment of valvular heart disease (15). 
In contrast to mitral valve degeneration,  Caira  et al. found that the Lrp5/Wnt3 signaling 
markers are present in the calcified aortic valve greater than the degenerative mitral valve. 
These data provide the evidence of a mechanistic pathway for the initiation of bone 
differentiation in degenerative valve lesions, which is expressed in the mitral valve as a 
cartilage phenotype and in the calcified aortic valve as a bone phenotype. These results 
indicate that there is a continuum of an earlier stage of osteoblast bone differentiation in the 
mitral valves as compared with the calcified aortic valves. In normal adult skeleton 
formation, the initiation of bone formation occurs with the development of a cartilaginous 
template, which eventually mineralizes and forms calcified bone. Therefore, the mitral valve 
expresses an early cartilage formation, and the aortic valve demonstrates the mineralized 
osteoblast phenotype,which follows the spectrum of normal skeletal bone formation. The 
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calcified aortic valves express an osteoblast phenotype: “bone” in the aortic valve that is 
responsible for the stenosis present in symptomatic aortic stenosis requiring surgical valve 
replacement. This study demonstrates that hypercholesterolemia may play a role in the 
initiating event of calcification. This is the first study to demonstrate the presence of 
chondrocytes in mitral valves, and osteoblasts in aortic valves implicating this pathologic 
mechanism in the development of mitral regurgitation in myxomatous mitral valves and 
stenosis in calcific aortic valves (16). In bicuspid aortic valve, the calcification and 
progressive stenosis typically occur faster than in tricuspid aortic valves, Rajamannan 
demonstred that the eNOS protein expression was decreased in the BAV vs. the tricuspid 
aortic valves. This data provides further evidence of the potential functional importance of 
eNOS enzymatic activity in the developmental level for the formation of the congenital heart 
abnormality in addition to the actual role in the calcification process. More, bone 
sialoprotein, osteocalcin, and osteopontin are increased and are markers of extracellular 
matrix synthesis in the valve whereas Notch1 is decreased in the valve. The protein and 
RNA expression also demonstrated a decrease in overall Notch1 in these disease tissues, 
indicating that the loss of normal Notch1 is necessary for valve calcification similar to the 
implications of the loss of function mutation in the genetic study. Overall, the loss of Notch1 
function and the increase in Lrp5 signaling demonstrate the role of these important 
regulators of bone metabolism in these diseased tissues. Than, the mechanism of BAVD 
results in a decrease in Notch1 function and an increase in Lrp5 expression which activates 
bone formation within the valve myofibroblast (17).   
2. Clinical presentation  
The diagnosis of the aortic stenosis is usually made on physical examination with detection 
of the classical systolic outflow murmur. The severity of aortic stenosis can be determined 
reliably by echocardiography, based on the extent of the valvular calcification, the peak flow 
velocity across the valve, the mean gradient and the valvular area computed by the 
continuity equation. Evaluation of serial echocardiograms in patients with aortic stenosis 
make it possible to obtain valuable information over a period of time to determine the 
progression of the disease and the timing of surgery (9). 
2.1 Signs and symptoms 
The classical symptoms of AS are angina, dispnea, syncope, and heart failure, which 
represent also the  dramatic inflection in the natural history of this disease.    
In adults with AS, the obstruction develops gradually. Many patients with aortic stenosis 
will remain asymptomatic for decades. The diagnosis of aortic stenosis is usually made in 
the asymptomatic patient on the basis of a systolic murmur on auscultation and confirmed 
by echocardiography. The development of symptoms therefore is a critical point in the 
natural history of patients with AS, infact the risk of sudden death in asymptomatic patient 
with  initial manifestation of severe aortic stenosis is very low (<1% per year ), but it is high 
once any symptom is present, so that valve surgery is appropriate with even mild 
symptoms.  
Most prospectively followed patients present with more subtle symptoms, typically 
decreased exercise tolerance, or dyspnea on exertion. It is not uncommon for patients to 
decrease their activity level below their symptom threshold—a careful history comparing 
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current and last year’s activity levels is needed to recognize that these patients, in fact, are 
symptomatic.   
In asymptomatic patients, the risks of valve surgery are weighed against the risk of an 
adverse outcome without surgical intervention. Aortic valve repair is not an option, so that 
the long-term durability and risks of a prosthetic valve also must be considered. (18) 
2.2 Diagnosis 
The physical examination, electrocardiogram, chest radiograph, echocardiography, and 
cardiac catheterization are important for  the diagnosis.  
The physical examination demonstrates a weak and slowly rising pulse (“parvus and 
tardus”).  Systolic ejection murmur is best heard at the base of the heart and is harsh in 
quality, but does not correlate with the severity of stenosis. 
The electrocardiogram demonstrated findings consistent with the presence of left 
ventricular hypertrophy and show an overload pattern. 
The chest radiograph has a normal appearance in the vast majority of patients. Left 
ventricular hypertrophy may be present and is demonstrated in the rounding of the left 
ventricular free wall. Severe calcification of the aortic valve can frequently be seen in adult 
patients with severe or critical aortic stenosis. 
Echocardiography is the most commonly used noninvasive diagnostic method for assessing 
the significance of aortic stenosis. Two-dimensional echocardiography can determine 
valvular motion and the presence or absence of valve thickening and calcification. However, 
Doppler echocardiography is necessary to assess the hemodynamic severity of the stenosis. 
Echocardiography is the clinical standard for evaluation of adults with suspected or known 
valvular AS. Anatomic images show the etiology of AS, level of obstruction, valve 
calcification, leaflet motion, and aortic root anatomy (19).   
It is important to determine the severity of aortic stenosis based upon hemodynamic 
measurements. The echocardiographic criteria were established to define the grading of 
stenosis by  ACC/AHA 2006 (20) and includes  the following: 
Valve area 
1. mild aortic stenosis: area > 1.5 cm2 
2. moderate aortic stenosis: area 1 to 1.5 cm2 
3. severe aortic stenosis: area < 1.0 cm2.  
Aortic velocity allows classification of stenosis as  
1. mild (less than  3.0 m/s) 
2. moderate (3 to 4 m/s) 
3. severe (>4 m/s). 
but in the revision and the update of ACC/AHA guidelines (2006) the grading of aortic 
stenosis in evaluated also by the transvalvular gradiente as following. 
1. mild (mean gradient less than 25 mm Hg) 
2. moderate (mean gradient 25 to 40 mm Hg) 
3. severe (mean gradient greater than 40 mm Hg) 
When stenosis is severe and ejection fraction (EF) is normal, the mean transvalvular 
pressure gradient  is normally greater than 40 mm Hg. However, when cardiac output is 
low, severe stenosis can be present with a lower transvalvular gradient and velocity. So to 
grade the severity of the stenosis also the Ef must to be evaluated. Doppler 
echocardiography is also used to determine diastolic dysfunction by the presence of 
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abnormal left ventricular relaxation.  Moderate to severe diastolic dysfunction does not 
increase early mortality but may increase late mortality after AVR. Stress echocardiography 
is used in patients with normal left ventricular function (LVF) to demonstrate the presence of 
diastolic dysfunction (i.e., signs of elevated left ventricular filling pressure) as the cause of 
symptom development during exercise. 
Doppler echocardiography has replaced cardiac catheterization in most centers for 
evaluation of the hemodynamic severity of aortic stenosis (21). Cardiac catheterization is 
reserved for hemodynamic evaluation in patients in whom reliable echocardiographic data 
cannot be obtained or when the clinical and echocardiographic data are divergent.  
Catheterization is also necessary in most patients undergoing aortic valve replacement 
(usually men with age > 40, post menopausal women, history of coronary artery disease and 
suspected myocardial ischemia or LV systolic dysfunction) to determine if there is 
associated coronary artery disease that can be treated at the time of operation (9).  
3. Predictors of Aortic Stenosis  
3.1 C reactive protein  
The dynamic and inflammatory nature of calcific aortic stenosis has been well appreciated 
in recent years, and many pathobiologic features of calcific aortic valve disease exhibit 
striking similarity to coronary atherosclerosis. C-reactive protein (CRP), which has been an 
useful predictive biomarker of the inflammatory process and prognosis of atherosclerosis, is 
increased in subsets of patients with calcific aortic stenosis, and this has led to the hope that 
CRP could be used as well to identify those patients likely to progress or develop severe 
calcific aortic stenosis (22).  
Recent data suggest that oxidative stress and high-sensitivity CRP plasma levels as a marker 
of systemic inflammation could be involved in the pathogenesis of rheumatic valve disease. 
Therefore, the role of inflammation in rheumatic valve disease progression should be 
considered. Indeed, the persistence of high levels of high-sensitivity CRP has been shown in 
patients with chronic rheumatic valve disease, particularly in patients with multivalvular 
disease, who showed significantly higher plasma levels of CRP (23).  
If inflammation is the fundamental process of early aortic valve disease, with calcification 
predominating in the later stages, one might anticipate that markers of inflammation, such 
as CRP, would reflect early aortic valve disease activity and perhaps be less useful as a 
marker in later stages. The available data do not support such a concept. CRP has been 
localized in the valve tissue of aortic stenosis in both native valves and bioprosthetic aortic 
valves, with a positive correlation between serum CRP values and valve CRP expression 
(24). C-reactive protein values are increased in patients with severe symptomatic aortic 
stenosis awaiting valve surgery compared with matched controls  and decline after aortic 
valve replacement. On the other hand, Navaro et al show that there is no relationship 
between elevated CRP levels and the presence of calcific aortic-valve disease or of  incident 
aortic stenosis. C-reactive protein appears to be a poor predictor of subclinical calcific aortic-
valve disease. They observed that older age, male gender, hypertension, coronary artery 
disease, and renal insufficiency, but not CRP values, are associated with the presence of 
increasing calcific aortic valve abnormality and that CRP values are not related to the 
progression from a normal aortic valve to aortic sclerosis or stenosis, nor progression from 
aortic sclerosis to aortic stenosis. African-American ethnicity was significantly protective 
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from developing calcific aortic valve disease. How do we make sense of these apparent 
discrepancies that CRP appears not to reflect the early inflammation phase of calcific aortic 
valve disease but does reflect the later calcific stages of the disease? The first methodologic 
consideration is that the single CRP value at study entry may have been too distant from the 
time that calcific aortic stenosis was developing during the follow-up period to reflect the 
inflammatory change that would later occur. It is also possible that the inflammatory 
process in early calcific aortic valve disease was not substantial enough to lead to an 
elevated serum value. It is also clear from the previously noted associations between CRP 
and severe aortic stenosis that CRP may be a more active, direct participant in the later 
stages of the disease progression and not simply a biomarker passively reflecting the early 
inflammatory stages of disease. CRP provides valuable prognostic information concerning 
adverse cardiovascular events in coronary disease as well, but it does not reflect the 
presence or severity of subclinical anatomic coronary artery disease (25). The study by 
Novaro et al.  does add important new understanding concerning the genetic determinants 
of calcific aortic valve disease. Genetic characteristics of calcium metabolism may be central 
to the development of valvular calcification, and the observation that African Americans are 
protected from development of calcific aortic valve disease, may be related to a genetic 
predisposition toward less calcification of vascular and valve tissue and lower incidence of 
osteoporosis. It would be of enormous value to identify a biomarker to predict patients 
likely to develop aortic sclerosis and those likely to progress to aortic stenosis. Only a few 
studies have examined the relationship between CRP and aortic stenosis. Galante et al. (6) 
published the initial study demonstrating elevated CRP levels in association with calcific 
aortic stenosis. In a surgical series, CRP levels were higher in severe aortic stenosis patients 
compared to patients with pure aortic regurgitation (26). In those who underwent aortic 
valve replacement for aortic stenosis, CRP levels decreased from before to 6 months after 
valve replacement. Recently, CRP has been localized in valve tissue of both calcific aortic-
valve stenosis and degenerative aortic-valve bioprostheses , with a positive correlation 
between serum CRP levels and valvular CRP expression. Thus, from the available human 
studies, it is apparent that CRP levels are elevated in aortic stenosis patients with severe 
disease awaiting surgery, do not correlate with stenosis severity, and decrease after valve 
replacement, supporting the histologic evidence that the aortic valve is a site of active 
inflammation. (5) 
3.2 Others predictors  
Whereas cardiovascular risk factors and CRP levels failed to predict incident aortic stenosis, 
only 4 demographic variables (increasing age, male gender, white ethnicity, and shorter 
height) were associated with an increased risk of incident aortic stenosis. Increasing age is a 
well-recognized risk factor related to aortic stenosis. Gender appears to have an impact on 
the risk of both aortic stenosis and the degree of aortic valve calcification , with men 
showing a greater predilection of both (5). 
Genetic factors can also be important in the development of valvular calcification. In a recent 
case–control study, 100 patients with similar demographic characteristics were compared, 
with and without aortic stenosis, and significant differences between the two groups were 
observed in the genotype of the vitamin D receptors (27). Another study identified 
polymorphisms of the apolipoproteins AI, B and E as predisposing factors for development 
of calcification and valvular stenosis (28). Finally, a unique study by Garg et al. 
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demonstrated the unique signaling pathway Notch as important in the development of 
calcific aortic stenosis and also congenital heart abnormalities. These important studies 
indicate that genetic predisposition and risk factors may play a role in the development of 
disease (9). In a recent study Kamalesh et al. revealed that diabetes accelerate progression of 
calcification in subjects who have moderately severe aortic stenosis. Therefore, for this 
patients may need intensive follow-up for their aortic stenosis rather than non diabetic 
subjects (29). The finding that the multifunctional glycophosphoprotein osteopontin (OPN) 
is involved in both cell-mediated inflammation and biomineralization has generated 
considerable interest in the role of OPN in ectopic calcification and calcific aortic valve 
disease as shown by Yu et al. (30). Although other serum markers, such as C-reactive 
protein and B-type natriuretic peptide have previously been shown to be associated with 
aortic calcification and stenosis, OPN is the only molecule that is implicated in both 
inflammation and biomineralization processes, which lead to aortic valve calcification and 
subsequent stenosis. Also Ferrari and Grau demonstrates a direct correlation of NT-pro-
BNP, BNP, and osteopontin and the presence of calcific AS, while fetuin A showed an 
inverse correlation. Plasma ADMA and homocysteine levels were comparable in the calcific 
AS patients and healthy individuals. A new study  analyzed osteopontin level and its 
phosphorilation status in CAVD and demostred that phospho-threonina levels of purified 
OPN are higher  in healthy controls when compared to CAVD patients.  This study showed 
that phospho-OPN prevent calcium deposition, whereas the dephosphorylated protein 
mimicking the patient’s plasma OPN, lose its protective role allowing calcium depositation 
on the cellular surface. This data suggest the role of circulating OPN and its phosphorilation 
status as biomarker and  inhibitory factor for the pathogenesis of calcific CAVD. (31) 
4. Treatment 
There are different choises of treatment, based on clinical symptoms, echocardiographical 
criterias and evaluation of risk factors.  
The development of symptoms in patients with severe aortic stenosis is associated with a 
50% mortality within a period of 5 years. Thus, symptomatic severe aortic stenosis is a clear 
class I recommendation for surgical intervention (21). At present, there is no medical 
treatment recommended for asymptomatic patients with aortic stenosis, and only clinical 
monitoring is recommended (5). 
However, recent epidemiologic studies evaluating the independent risk factors for calcific 
aortic stenosis have demonstrated that the risk factors for aortic stenosis are similar to those 
of coronary artery disease, which include hypertension, elevated low-density lipoprotein, 
smoking, diabetes, and male gender (32). These atherosclerotic risk factors provide the 
evidence for the potential of medical therapy for this disease process. (19) 
4.1 Initial treatment 
The management of patients with aortic stenosis depends upon the severity of aortic 
stenosis and the presence or absence of symptoms. In patients with only mild stenosis and 
no symptoms, management is continued observation. Serial echocardiography should be 
performed every 3 years in  patients with mild aortic stenosis and every 1–2 years in those 
with moderate stenosis. Prompt echocardiography should be performed anytime there is 
new symptom onset. Infective endocarditis prophylaxis should be followed. Patients with 
moderate-to-severe aortic stenosis should avoid athletics, which require high dynamic and 
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static muscular demands. There are no proven medical treatments to slow or prevent 
disease progression. However, aggressive lipid lowering therapy may be of benefit, 
especially in patients with less-severe valve calcification, and will ameliorate progression of 
vascular atherosclerosis that frequently coexists and increases their comorbidity. Patients 
with symptoms and severe aortic stenosis should be considered for operation with aortic 
valve replacement. Delays to surgery have been associated with poorer outcome following 
operation Over the past two decades, the risk of operation has decreased substantially. 
Isolated aortic valve replacement in a patient less than 70 years old should be able to be 
performed with a risk of less than 1%. The risk should be less than 2–3% among 
septuagenarians and even less than 5% in octogenarians in the absence of significant 
comorbidities. Therefore, age is not a contraindication to surgery. Concomitant coronary 
artery bypass grafting should be performed for coronary atherosclerosis when epicardial 
lesions are >50%. 
Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, 
different studies hypothesized that people with elevated high-sensitivity C-reactive protein 
levels might benefit from statin treatment. (33) The treatment of the asymptomatic patient 
with severe aortic stenosis is more controversial. When there is left ventricular dysfunction, 
valve replacement is indicated even in asymptomatic patients. In these patients, the critical 
increase in afterload has started to overwhelm the compensatory mechanisms of left 
ventricular hypertrophy and the outcome is poor without surgical intervention. 
Importantly, aortic valve replacement can also now be done with a low operative mortality 
and there is enhanced durability of the new prostheses. Thus, surgery is reasonable to 
consider in asymptomatic patients when there is critical aortic stenosis and the expected 
operative mortality is <1.0%. Aortic valve replacement may also be considered for adults 
with severe asymptomatic aortic stenosis if there is evidence or high likelihood of rapid 
progression or when there may be delayed rapid access to medical care if symptoms arose. 
Progression of aortic stenosis may be considered rapid when the Doppler peak velocity 
increases by >0.3 m/s per year or when the valve area decreases by >0.1 cm2 per year .  
4.2 Future directions in medical treatment  
As greater understanding of the cellular mechanisms, pathogenesis and progression of 
aortic valvular disease evolves, new pharmacological strategies are being proposed that are 
targeted more directly to mechanisms of the disease, both for preventing its progression and 
ultimately for achieving its regression. The two pharmacological agents that have been 
studied experimentally and that demonstrate the most potential benefit are the HMG-CoA 
reductase inhibitors (statins) and the ACE inhibitors (19,20,22,33). The clinical 
implementation of these pharmacological treatments will require a strict validation of the 
experimental and retrospective studies to date (34–38), in order to establish a clear cause–
effect benefit in any pharmacological treatment system.  
Conventionally ACE-Is are contraindicated in patients with severe AS. However, we may 
safely administer ACE-Is to patients with mild AS because hemodynamic effects of stenotic 
aortic valve are well compensated in such patients. The renin-angiotensin system 
contributes to the inflammatory nature of the aortic valve lesion. Angiotensin converting 
enzyme (ACE), as well as angiotensin II and the angiotensin II type-1 receptor, have been 
identified in aortic sclerotic lesions , which stimulate monocyte infiltration and macrophage 
uptake of modified LDL (34). Calcification, the hallmark characteristic of aortic valve 
stenosis, is also clearly a feature of the active inflammatory process, occurring in valve 
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regions of lipid disposition, especially oxidized lipids, with additional stimulus provided by 
macrophage- and T lymphocyte-produced cytokines. Early in the disease process, active 
microscopic areas of calcification are seen co-localizing in areas of lipoprotein accumulation 
and inflammatory cell infiltration; as the disease progresses, active bone formation is seen.  
ACE inhibitors are thought to interfere with the renin-angiotensin system and exert 
beneficial actions on vascular tissues beyond their blood pressure–lowering effects.  
Regarding statins, there are a number of experimental models testing the effects of a 
cholesterol diet on the aortic valve in mice model. Sarphie (39) demonstrated the first 
histochemical effects of cholesterol on the development of valvular heart disease.  Studies by 
Rajamannan  and Charest et al have also shown that endothelial nitric oxide enzyme activity 
plays a role in the early valve lesions. Elevated cholesterol decreases the enzyme expression 
and induces early mineralization in the aortic valve. Therefore, these early studies provide 
the evidence that aortic valve disease has similar initiating mechanism of oxidative stress 
that is found in vascular atherosclerosis. The next critical step toward understanding of 
aortic valve calcification is to determine the signaling mechanisms involved in the 
development of this disease (40). The studies from Mohler (41) and Rajamannan (40) have 
shown that the aortic valve calcifies secondary to a bone phenotype. Recent studies from 
Rajamannan and Shao et al. have demonstrated that the mechanism by which calcification 
develops is activation of the LDL receptor 5 (Lrp5)/Wnt pathway in the vascular and 
valvular interstitial cells (40). These studies confirm that the presence of bone formation is 
the phenotypic expression of calcification in the aortic valve (10). Over time, the valve leaflet 
synthesizes bone matrix, which eventually calcifies and forms bone. If the aortic valve has 
an actual biology that is initiated by elevated cholesterol, then in the future, medical therapy 
such as statins or angiotensin-converting enzyme inhibitors may slow the progression of 
this disease.  
Also Nagy et al. studied the role of proinflammatory signaling through the leukotriene (LT) 
pathway in aortic stenosis and demonstred that the messenger RNA levels of the LT-
forming enzyme 5-lipoxygenase increased in thickened and calcified tissue compared with 
normal areas of the same valves. Moreover they showed that leukotriene C4 (LTC4) 
increased intracellular calcium, enhanced reactive oxygen species production, reduced the 
mitochondrial membrane potential, and led to morphological cell cytoplasm changes and 
calcification. This data suggest the up-regulation of the pathway LT and the potentially 
detrimental LT-induced effects on valvular myofibroblasts as possible role in the 
development of aortic stenosi and induce to considerate innovative therapeutic 
interventions(42). 
The first landmark randomized, prospective trial published in this field, Scottish Aortic 
Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE), (43) demonstrated, 
however, that high-dose atorvastatin does not slow the progression of this disease. SALTIRE 
initiated atorvastatin in patients who had more advanced aortic stenosis as defined by the 
mean aortic valve area of 1.03 cm2, with heavy burden of calcification as measured by aortic 
valve calcium scores. Newby et al recently acknowledged that the timing of therapy for 
aortic valve stenosis may play the key role in the future treatment of this disease. The 
important issue may be treating this disease earlier in its process to slow the progression of 
bone formation in the aortic valve (44). The potential benefit of statin therapy, however, is 
controversial and widely debated, as recent randomized studies done in patients with 
moderate to severe degrees of aortic stenosis failed to consistently show substantial benefits 
of this class of drugs. Antonini et al. provides evidence for a positive effect of statins in 
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reducing the progression of rheumatic AS and in a large series of patients with long-term 
follow-up, statins were effective in slowing the progression of aortic valve disease in aortic 
sclerosis and mild AS, but not in moderate AS. These results suggest that statin therapy 
should be taken into consideration in the early stages of this common disease (23). The 
RAAVE (Rosuvastatin Affecting Aortic Valve Endothelium) study suggests that earlier 
treatment with statins is more efficacious in the prevention of progression of aortic valve 
stenosis than late treatment, similar to the effects of statins in the regression of vascular 
atherosclerosis (45). Importantly, results of the randomized trials will provide further 
evidence to define the treatment of this complex disease process, in which timing of therapy 
and characteristics of the valve lesion will need to be taken into account in the future 
treatment approaches. In the RAAVE trial, the rate of progression of aortic stenosis in those 
with hypercholesterolemia treated with rosuvastatin is slower than in those with lower lipid 
levels who are not treated. This is the first study to provide positive clinical evidence for the 
potential of targeted therapy in patients with asymptomatic aortic stenosis (45). Finally 
Parolari et al. (46) performed a meta-analysis of studies was performed comparing statin 
therapy with placebo or no treatment on outcomes and on aortic stenosis progression 
echocardiographic parameters. This meta-analysis identified 10 studies with a total of 3822 
participants (2214 non-statin-treated and 1608 statin-treated). No significant differences 
were found in all-cause mortality, cardiovascular mortality or in the need for aortic valve 
surgery. Lower-quality (retrospective or non-randomised) studies showed that, in statin-
treated patients, the annual increase in peak aortic jet velocity and the annual decrease in 
aortic valve area were lower, but this was not confirmed by the analysis in high-quality 
(prospective or randomised) studies. Statins did not significantly affect the progression over 
time of peak and mean aortic gradient. Taken together, this evidences suggest that the 
progression of calcific aortic stenosis is a complex process; the multitude of the mechanisms 
involved in AS  indicates that drug therapy should address the earliest stages of the disease, 
as it is now evident that pharmacological treatment administered in more advanced stages 
of the disease may be ineffective (47).  At the end, all studies of statins have had the “wrong 
target” trying to treat patients with severely calcified valves. In our opinion we should treat 
patients at earlier stages of the disease, since statins side-effects are considered marginal and 
moreover statins have been proven beneficial to delay atherosclerosis progression and CAD, 
than quite often accompany AS.  
4.3 Surgical treatment 
Aortic valve replacement is indicated in patients who have severe aortic stenosis in the 
absence of other major comorbidities. Patients who undergo aortic valve replacement have 
an improvement in symptoms and increased survival after valve replacement surgery. 
Currently, there is no indication for surgical valve replacement in patients who have 
asymptomatic critical aortic stenosis unless they have left ventricular dysfunction or 
abnormal hemodynamic response to exercise. Patients who have moderately depressed 
ventricular function do as well as those with normal ventricular function. Depressed 
ventricular function may be due to afterload mismatch or an intrinsic depression of 
contractility. Both the safety and prognosis of aortic valve replacement relate to 
distinguishing between these two causes of reduced ventricular function. Patients with true 
afterload mismatch do well after aortic valve replacement despite very low ejection 
fractions. Depressed contractility from myocardial disease does not respond as well to aortic 
valve replacement (19) 
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Aortic valve replacement in patients without symptoms is controversial, infact 
asymptomatic patients with AS have outcomes similar to age-matched normal adults. While 
the short-term prognosis in such patients is excellent without surgery, there is still a small 
but definite risk of sudden death. Obviously there is also a small but definite risk of 
morbidity and mortality related to aortic valve replacement and to complications resulting 
from the presence of a prosthetic valve. 
4.4 Aortic valve replacement 
When planning AVR, the chief issues related to surgical decision making involve the type of 
valve prosthesis to be inserted, the timing of surgery, and issues related to concomitant 
procedures. The ideal prosthesis for AVR is characterized by excellent hemodynamics, 
minimal residual transvalvular pressure gradient, and laminar flow through the prosthesis. 
In addition, the valvular prosthesis should be durable, easy to implant, quiet, biocompatible, 
and resistant to thromboembolism. The two major categories of valvular prostheses, which 
account for the vast majority of implanted aortic valves, include mechanical and 
bioprosthetic valves. Regarding the decision between bioprosthetic and mechanical valves, 
the primary advantage of mechanical valves is their durability and 
reliable performance.  Conversely, the primary disadvantage of mechanical valves relates to 
the need for lifelong warfarin anticoagulation and attendant lifestyle limitations and 
thromboembolic (TE) and bleeding risks. When anticoagulation is managed appropriately, 
the risk of TE with mechanical valves is similar to that for bioprosthetic valves. Bileaflet 
mechanical valves are the standard in current practice. Conversely, the primary advantage 
of bioprosthetic valves is that systemic anticoagulation with warfarin is not required. As a 
result, patients receiving tissue valves have a lower rate of anticoagulation-related bleeding 
complications. However, their limited durability (freedom from structural valve 
deterioration and need for reoperation) and suboptimal hemodynamics, due to a generally 
smaller effective orifice area size-for-size as compared to mechanical valves, have 
historically been the drawbacks of bioprosthetic valves. As a result, use of bioprosthetic 
valves has generally been recommended for patients older than 65 years of age or with 
reduced life expectancy. These tendencies are nowadays changing in light of improved 
tissue engineering, the increased lifespan of new generation tissue valves and the relative 
low risk of reoperation for isolate valve re-replacement. Moreover, the increasing trend to 
use transcatheter aortic valve implantation (TAVI) and the possibility to replace a 
previously implanted biological prosthesis with the method of valve in valve, the 
implantatation of a trancatheter valve into the old and degenerated prothesis, without a new 
open heart operation, moves the needle of the balance toward greater use of biological 
prosthesis, even if the duration of TAVi in young patient is not still known.  
The most important problem in the use of mechanical prosthesis is anticoagulation for all 
the life. Anticoagulation for the long-term treatment has been accomplished by vitamin K 
antagonists for the last half century. Although effective under optimal conditions, the 
imminent risk of a recurrent adverse event of INR the risk of bleeding due to the narrow 
therapeutic window, numerous food- and drug interactions, and the need for regular 
monitoring complicate the long-term use of these drugs and render treatment with these 
agents complicated. But new anticoagulants which selectively block key factors in the 
coagulation cascade are being developed (48). Dabigatran is the first available oral direct 
thrombin inhibitor anticoagulant, it specifically and reversibly inhibits thrombin, the key 
enzyme in the coagulation cascade. Its oral bioavailability is low, but shows reduced 
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interindividual variability. Studies show a predictable pk/pd profile that allows for fixed-
dose regimens. The anticoagulant effect correlates adequately with the plasma 
concentrations of the drug, demonstrating effective anticoagulation combined with a low 
risk of bleeding. Rivaroxaban will probably be the first available oral factor Xa (FXa) direct 
inhibitor anticoagulant drug. It produces a reversible and predictable inhibition of FXa 
activity with potential to inhibit clot-bound FXa. Its pharmacokinetic characteristics include 
rapid absorption, high oral availability, high plasma protein binding and a half-life of aprox 
8 hours. (49) 
The development of new anticoagulant, safer , with less risk of bleeding, and which allow to 
the patient the possibility of a fixe assumption, without monitoring INR every week, could 
change the choice criteria between biological and mechanical prosthesis. 
4.5 Aortic balloon valvotomy 
Percutaneous balloon aortic valvotomy (BAV) is a procedure in which 1 or more balloons 
are placed across a stenotic valve and inflated to decrease the severity of AS. Although  BAV 
is useful in children with congenital AS, the calcified lesion of acquired AS in the adult does 
not respond well to BAV. After a modest acute reduction in stenosis severity, restenosis 
recurs usually within 6 months. Immediate hemodynamic results include a moderate 
reduction in the transvalvular pressure gradient, but the postvalvotomy valve area rarely 
exceeds 1.0 cm2. Despite the modest change in valve area, an early symptomatic 
improvement is usually seen. However, serious acute complications occur with a frequency 
greater than 10% (50, 51). 
5. The future 
Prolonged life expectancy has resulted in an aging population and, consequently, in an 
increased number of patients with degenerative calcific aortic stenosis (52). AS has increased 
markedly in developed countries and AS, caused by valve calcification in the elderly, will 
continue to increase as the aging of society accelerates. For symptomatic patients with 
severe aortic valve stenosis, open heart surgery for aortic valve replacement (AVR) with use 
of cardioplegia under cardiopulmonary bypass remains the gold standard. Although 
surgery is still the gold standard treatment, it is considered high risk in elderly patients 
because of high complication rates, which leads to substantial hesitation in submitting such 
patients to surgery. The surgical approach is associated with substantial operative mortality 
rates in high-risk patients. Consequently, almost one-third of patients with severe aortic 
stenosis are not offered surgery owing to a combination of reasons such as advanced age, 
impaired left ventricular function, re-do procedure, or multiple comorbidities (50). 
Moreover, as longevity within the general population is increasing, the proportion of aortic 
stenosis patients with contraindications for surgery is also expected to increase. Decision-
making is particularly complex in the elderly who represent a heterogeneous population, 
resulting in a wide range of operative risk, as well as life expectancy, according to 
individual cardiac and non-cardiac patient characteristics. The two most striking 
characteristics of patients who were denied surgery were older age and LV dysfunction. 
Age and LV dysfunction are associated with an increased operative risk and a poor late 
outcome after surgery, which may explain the reluctancy to operate on such patients. Age is 
a strong predictor of operative risk and poor late survival in cardiovascular surgery, in 
particular, in the case of AS. Four percent of the elderly population has significant aortic 
www.intechopen.com
 
Aortic Stenosis – Etiology, Pathophysiology and Treatment 
 
16
stenosis  and the size of the population older than 65 years will grow 50% between 2000 and 
2030.  In very old patients with many comorbidities, the outcome of AVR is less favourable 
than in average poulation, and many of those patients may be inoperable or carry an 
unacceptably high perioperative risk. Some patients with aortic valve disease defer surgery 
in light of mild symptoms, whereas others are deemed too ill to undergo cardiac surgery. 
The latter currently have been treated expectantly or by balloon aortic valvuloplasty (BAV), 
but this technique offers poor magnitude and durability of the physiologic improvement in 
aortic valve orifice area. In most patients, balloon valvotomy reduces severe AS to 
moderately severe AS. The gradient typically is reduced by 50% and averages 
approximately 35 mm Hg after the procedure. Unfortunately, in 50% of patients, restenosis 
occurs within 6 months. Overall, balloon valvotomy has not reduced the high mortality seen 
in patients who do not undergo surgery for symptomatic AS. Recent technological 
advances, however, now indicate that catheter techniques similar to those used for BAV can 
be used for percutaneous aortic valve replacement, avoiding open cardiac access or the use 
of cardiopulmonary bypass.  As with any medical procedure, the risk/benefit ratio of TAVI 
must be carefully considered. The benefits provided by this novel procedure must be 
weighed eventually against what is considered today the “gold standard” that is surgical 
AVR. Bearing in mind, however, the excellent track record of surgical AVR, it seems 
prudent to initially target those patients who are at high surgical risk due to severe 
comorbidities. Thus, the patients currently enrolled in these studies are chosen based on a 
risk score, such as the EuroSCORE or STS score. The other set of patients who may be 
considered at present are those with a deteriorated aortic bioprosthesis and deemed at high 
risk for surgical reoperation, and this “valve-in-valve” concept has already been reported. 
With technological advancements, it is expected that the ease of implantation will improve 
and complications will decrease. In order to consider lower risk and younger patients as 
candidates for this new technology, additional long-term durability data will be required 
before advocating this procedure as a possible substitute to surgical AVR. Risk algorithms 
have been used to assess operative risk, anticipate outcomes, and provide for comparability 
of patients among diverse centers and countries. Unfortunately, these tools are inherently 
imprecise and frequently exclude comorbidities encountered in this population. Therefore, 
the comparison of transcatheter procedural outcomes to anticipated results based upon 
predictive risk scoring remains somewhat subjective. The presence of CAD has been clearly 
demonstrated to increase procedural risk with conventional aortic valve replacement. 
However, its overall influence on outcomes of transcatheter therapy for aortic stenosis has 
not been clearly delineated. This is especially true given the fact that TAVI is generally 
considered a stand-alone procedure, with variable degrees of concomitant coronary artery 
disease tolerated without intervention. It has been shown that patients with CAD as 
indicated by previous CABG or PCI had significantly higher 30-day and overall mortality 
with transcatheter valve implantation. 
6. Risk stratification  
The Euro Heart Survey has shown that, in current practice, there is general agreement 
between the decision to operate and the existing guidelines in asymptomatic patients. 
However, in patients with severe symptoms, intervention is underused for reasons that are 
often unjustified. This stresses the importance of the widespread use of careful risk 
stratification. In the absence of evidence from randomized clinical trials, the decision to 
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intervene in a patient with VHD relies on an individual risk–benefit analysis, suggesting 
that improvement of prognosis compared with natural history outweighs the risk of 
intervention and its potential late consequences, in particular, prosthesis-related 
complications. Factors predicting operative mortality have been identified from large series 
of patients undergoing cardiac surgery or, more specifically, heart valve surgery. They are 
related to heart disease, the patient’s age, comorbidity, and the type of surgery. The easiest 
way to integrate the weight of the different predictable factors is to combine them in 
multivariate scores, enabling operative mortality to be estimated.  
6.1 Euroscore 
It is a risk model which allows the calculation of the risk of death after a heart operation. 
The model asks for 17 items of information about the patient, the state of the heart and the 
proposed operation, and uses logistic regression to calculate the risk of death. First 
published in 1999, the model has been adopted worldwide, becoming the most widely used 
risk index for cardiac surgery, and its use is believed to have contributed substantially to the 
improvement in the results of heart surgery seen at the beginning of the millennium. It is 
now aging and a new model (EuroSCORE 2010) is being prepared. Briefly, comprehensive 
data were obtained for over 19,000 consecutive patients undergoing open heart surgery in 
128 centers in eight European countries. The database thus generated was subjected to 
multiple logistic regression analysis to determine which risk factors were associated with 
operative mortality. Weights were allocated to each risk factor on the basis of the odds ratios 
and a risk model was constructed in which the percentage predicted mortality for a patient 
could be calculated by adding the weighted values of risk factors which are present.  The 
additive EuroSCORE model, by virtue of its nature, tends to underestimate risk in very 
high-risk patients. Some very high-risk patients may be better assessed, for individual risk 
prediction, by using the full logistic EuroSCORE model. EuroSCORE was initially designed 
to be a user-friendly system, in the hope of encouraging as many units as possible to embark 
on programs of risk-adjusted quality monitoring. In this setting, although derived from a 
logistic regression methodology, only the simple additive version of the score was originally 
published. This score could be easily calculated at the bedside and could therefore be used 
widely in Europe even in hospitals with little information technology. Using the same risk 
factors, the logistic regression version of the score (the ‘logistic EuroSCORE’) can be 
calculated. Many risk factors have been associated with cardiac surgical mortality and 
morbidity. The EuroSCORE was derived from data obtained from patients operated on in 
1995, and the details were first published in 1999. The system is now 10 years old, and is 
based on data that are even older. Yet, since the introduction of EuroSCORE, there has been 
a quantum improvement in cardiac surgical survival which mainly occurred during the first 
two to three years of the new millennium. Evidence from countries with national databases 
has suggested that mortality in some of these countries has approximately halved, despite a 
gradual worsening of the risk profile of patients. In the United Kingdom, for example, 
mortality has fallen to approximately 55% of logistic EuroSCORE prediction, giving a UK 
RAMR (risk adjusted mortality ratio obtained dividing the actual mortality by the predicted 
mortality) of around 0.55. In a consecutive series of patients with severe AS undergoing 
AVR, Kalavrouziotis and coworkers found that the logistic EuroSCORE was not an accurate 
risk assessment tool in all categories of risk but especially in high-risk patients. Therefore, 
this predictive model should not be used to determine procedural risk in patients with 
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severe AS. Furthermore, the utilization of the logistic EuroSCORE in the assessment of 
operability in patients with severe AS may not be appropriate.  
6.2 STS (Society of Thoracic Surgeons) risk score  
More than 20 years ago, the STS was one of the first specialty organizations to recognize the 
importance of developing a prospectively maintained clinical data registry. The resulting 
STS National Adult Cardiac Surgery Database (STS NCD) has achieved widespread 
acceptance by the provider community as well as interested third parties, including health 
policy researchers, government regulators, accrediting agencies, and payers. The Society of 
Thoracic Surgeons’ risk models predict the risk of operative mortality and morbidity after 
adult cardiac surgery on the basis of patient demographic and clinical variables. The models 
are primarily used to adjust for case mix when comparing outcomes across institutions with 
different patient populations. The STS currently has three risk models: CABG, Valve, and 
Valve + CABG. The models apply to seven specific surgical procedure classifications: 
CABG model 
1. Isolated Coronary Artery Bypass (CABG Only) 
Valve model 
2. Isolated Aortic Valve Replacement (AV Replace) 
3. Isolated Mitral Valve Replacement (MV Replace) 
4. Isolated Mitral Valve Repair (MV Repair) 
Valve + CABG model 
5. Aortic Valve Replacement + CABG (AV Replace + CABG) 
6. Mitral Valve Replacement + CABG (MV Replace + CABG) 
7. Mitral Valve Repair + CABG (MV Repair + CABG) 
New STS models, developed using STS data from 2002 to 2006, account for endpoints as for 
operative mortality, permanent stroke, renal failure, prolonged ventilation (> 24 hours), 
deep sternal wound infection, reoperation for any reason, a major morbidity or mortality 
composite endpoint, prolonged postoperative length of stay, and short postoperative length 
of stay. Recently, the STS risk algorithm was reported to be the most sensitive score in 
defining the risk of patients undergoing isolated AVR. Predictive value of many of the 
currently available scoring systems is insufficient to allow a reliable risk assessment in 
patients undergoing isolated aortic valve replacement. The overestimation is most 
prominent in high-risk patients. Risk stratification using the STS score was accurate in 
predicting the risk of mortality in high-risk patients. Nevertheless, even this most recently 
built score systematically overestimates procedural risk. From the clinician’s standpoint 
there is a need for an objective risk assessment tool. 
6.3 Do we need new or better tailored risk models?  
Risk stratification models for operative mortality have gained widespread acceptance in 
cardiac surgery. These models, however, are not 100% accurate. A number of factors can 
influence their performance. Generally speaking, available risk models for cardiac surgery 
can be divided into three categories: (1) general cardiac surgery models - that is, coronary 
artery bypass surgery, valve surgery or other related cardiac surgery; (2) general valve 
surgery models; and (3) specific aortic valve surgery risk models. Risk models can serve 
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multiple purposes if used correctly. Firstly, risk models can be used for benchmarking; they 
may allow for control of procedural complexity when analyzing hospital and surgeon 
performance. Secondly, risk models can help educate patients and improve informed patient 
consent. Risk models can also be incorporated into guidelines to help identify high risk 
patients who may benefit from additional work-up or alternative treatment strategies. If risk 
models can accurately identify high risk patients with expected longer lengths of stay in 
hospital, they may be useful for administrative logistic and budget planning. Differences in 
epidemiology of disease, risk profiles, surgical strategies, decision making, selection bias, 
and referral bias can all influence the applicability and performance of a model. Regarding 
EuroScore performance in valve surgery Parolari suggested that  EuroSCORE might not be 
the appropriate tool for risk prediction in isolated valve operations or those combined with 
other cardiac procedures. The area under the curve (AUC) derived from the meta-analysis 
he performed provided estimates of 0.72 to 0.74, which are in a range of a performance 
considered less than satisfactory for a risk stratification algorithm. EuroSCORE 
discrimination is also substantially lower with respect to the performance of the Society of 
Thoracic Surgery (STS) algorithm, which is about 0.8 for isolated valve operations and about 
0.75 for valves plus CABG. The explanation for this is that the STS score is updated almost 
annually, and, for this reason, it may better follow the changes occurring in valve patient 
population with relative ease, whereas the EuroSCORE is now undergoing its first revision 
since its introduction. The discriminatory power and precision in risk prediction of the 
EuroSCORE in valve surgery has recently become increasingly important for two reasons. 
The first is that in the most centers, valve procedures—either isolated or combined - actually 
represent more than 50% of the total caseload; therefore, accurate risk estimation in this 
patient population—mainly elderly and very elderly people—has become much more 
important. The second reason is strictly related to the recent evolution in technical options in 
aortic valve operations that has led to a steady increase in the adoption of transcathether 
aortic valve procedures in patients at the highest risk or in very elderly people.   
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